Introducing You to the First Ampligen Quarterly Update

Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the release of what will be the first of many Corporate Quarterly Updates to provide stockholders and investors information on the most recent advances in our oncology work each financial quarter.

“It is our intention to update our progress in immuno-oncology on a quarterly basis mid-month every three months so the market, potential co-development candidates in big pharma, research analysts and the media have easy access to updated information, which will be a precursor to and mirror to the greatest extent possible our subsequent quarterly filings,” said Hemispherx CEO Thomas K. Equels.

Read the full announcement here.

Hemispherx News 04

Need More Info?

Let’s Talk